ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1374

Secukinumab in the Treatment of Dactylitis in Patients with Psoriatic Arthritis: Post Hoc Analysis Results from a Randomized Phase 3 Trial
Abstract Number: 1375

Remission in Axial Spondyloarthritis: Is There a Difference Between NSAIDs and Biologics in the Real Life?
Abstract Number: 1376

Impact of Body Composition Measures on the Response to Biological Disease-modifying Anti-rheumatic Drugs in Patients with Ankylosing Spondylitis
Abstract Number: 1377

Raynaud’s Phenomenon and Systemic Sclerosis in Post-9/11 Deployed Veterans Receiving Care Veterans Health Administration Care
Abstract Number: 1378

Understanding Diagnostic Pathways in Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Abstract Number: 1379

Clinical Outcomes Among Participants with Diffuse Systemic Sclerosis Contracting COVID-19 During Clinical Studies of Lenabasum: A Case Series
Abstract Number: 1380

Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Increases the Risk of Digital Ischemic Complications in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
Abstract Number: 1381

Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset
Abstract Number: 1382

Changes in Imaging Markers in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib: Sub-Study of the SENSCIS Trial
Abstract Number: 1383

Tocilizumab Shows Potential in Preserving Lung Function in Systemic Sclerosis with Positive anti-topoisomerase-1 (Scl-70): A Single Centre Cohort Study
Abstract Number: 1384

Usage, Needs and Preferences Regarding Physical Therapy in Patients with Systemic Sclerosis
Abstract Number: 1385

Physical Therapy in Patients with Systemic Sclerosis: The Perspective of Physical Therapists on Current Delivery and Educational Needs
Abstract Number: 1386

Clinical Correlates and Relevance of the UCLA GIT 2.0 Instrument for Indication for Esophagogastroduodenoscopy and Endoscopic Esophagitis in Real-life Patients with Systemic Sclerosis
Abstract Number: 1387

Should Systemic Sclerosis Patients with Low Bicarbonate Have Replacement to Prevent Renal Dysfunction?
Abstract Number: 1388

A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].